London Daily

Focus on the big picture.
Friday, Jan 24, 2025

From COVID to Cancer: Pfizer's Shopping Spree Continues with $43 Billion Seagen Acquisition

Pfizer is looking beyond the COVID-19 pandemic and making some major moves in the world of cancer treatments. The pharmaceutical giant has just announced a $43 billion deal to acquire Seagen, a leading innovator in targeted cancer therapies.
This latest acquisition by Pfizer will add four approved cancer therapies to their portfolio, which together generated nearly $2 billion in sales in 2022. Seagen is a pioneer in antibody-drug conjugates, which essentially work like "guided missiles" designed to target and destroy cancer cells while leaving healthy cells unharmed.

CEO Albert Bourla says that this deal will help Pfizer move into an area that is more protected from regulatory and patent issues. It's also a smart move for Seagen, as the Biden administration's Inflation Reduction Act is set to benefit the company's expensive treatments, which will be more accessible to patients with out-of-pocket healthcare spending caps.

Pfizer will pay $229 in cash per Seagen share, a 32.7% premium to Friday's closing price, which sent Seagen's shares soaring to $200 in early trading.

This acquisition comes as Pfizer is preparing for a significant decline in COVID-19 product sales and stiff competition for some of its top-selling drugs. The company expects to generate more than $10 billion in sales from Seagen products alone by 2030, in addition to the $15 billion from its other recent acquisitions.

Pfizer's recent deals include the purchase of Global Blood Therapeutics for $5.4 billion, migraine drug maker Biohaven Pharmaceutical Holding for $11.6 billion, and drug developer Arena Pharmaceuticals for $6.7 billion.

Pfizer's current portfolio of oncology therapies includes 24 approved drugs, while Seagen's includes Adcetris for lymphoma, Padcev for bladder cancers, Tivdak for cervical cancer, and breast cancer treatment Tukysa.

The deal is expected to be completed in late 2023 or early 2024, and while antitrust regulators may closely review it due to its size, Pfizer believes it will eventually be approved.

This is definitely one to watch as Pfizer makes bold moves in the world of cancer treatments and continues to diversify its portfolio beyond COVID-19 products.
Comments

Oh ya 2 year ago
Maybe they are doing this because of the spike in cancer in people who have taken the clot shot. Making money at both ends.

Newsletter

Related Articles

0:00
0:00
Close
President Trump Orders Declassification of JFK, RFK, and MLK Assassination Records
President Trump Signs Executive Order to Bolster U.S. AI Leadership
Germany’s Democracy Under Strain: Political Labeling Sparks Free Speech Concerns
The Trump Era 2: A Time of Dramatic and Profound Change
BlackRock CEO Larry Fink Suggests Bitcoin Could Reach $700,000 with Increased Institutional Investment
Leaked Documents Reveal Google's Collaboration with Israeli Defense Forces During Gaza Conflict
Trump to Announce $500 Billion AI Infrastructure Investment
Dear President Donald Trump, I want to assure you that this fraud does NOT reflect the opinions of the majority of decent British citizens.
Olaf Scholz vs. Elon Musk: A Battle Over Common Sense, Which Scholz Appears to Be Missing
EU’s Overregulation Drives Innovation Collapse and Brain Drain
Five Billionaires on Track to Break One Trillion Dollar Wealth Barrier
TikTok Restored in the U.S. Following Trump inauguration
Bill Ackman Praises Social Media Platform X as 'The New Media'
Argentina Achieves Record Trade Surplus in 2024 Under President Milei
Italian Prime Minister Giorgia Meloni Proposes Rome as European Union Capital
France Urges EU to Act on Musk's Political Influence as Tensions Rise
Former Special Forces Blast Defense Ministry for Revealing Sensitive Details
Celebrity Responses to California Wildfires: Charity, Criticism, and Controversy
The Wildfires of Los Angeles: A Devastating Impact on Celebrities and California's Leadership
Tragic Loss: Teenager's Death Sparks Community Reflection in Bedford and London
UK Government Proposes Cap on Resale Ticket Prices to Combat Touts
Greenland's Future Caught in Diplomatic Crossfire Between Trump and Europe
EU Prepared to Lead Support for Ukraine Amid US Uncertainty, Says Estonian Prime Minister
Brompton E-Bike Component Diverted to UK Military Drone Production, Causes Delays
Romanian Gang Convicted of Human Trafficking and Exploitation in Dundee
Persistent Cold Snap Grips the UK: Severe Frost and Snow Disrupt Daily Life
Germany Faces Alarming Rise in Homelessness, New Report Shows
China’s Appetite for Salmon: A Game Changer in Global Seafood Markets
Russian Bots Allegedly Amplified NATO Critic Prior to Croatian Election, Researchers Reveal
Armenia Considers EU Membership Referendum Amid Strained Ties with Russia
French Finance Minister Explores Pension Reform Compromise to Secure Budget Agreement
Armenia Considers EU Referendum Amid Growing Rift with Russia
New Wildfire Ignites in Los Angeles as Region Battles Devastating Blazes
The Espionage Unraveled: A Russian Spy Network's Intricacies in the UK
U.S. Supreme Court Rejects Trump's Bid to Delay Sentencing in Hush Money Case
UK Financial Markets Remain Calm Amid Rising Government Borrowing Costs
Stellantis Achieves UK Electric Vehicle Sales Mandate Amid Factory Closure
TikTok Faces Potential Ban in the United States Amid Security Concerns
Pound Plummets to 14-Month Low Amid Concerns Over UK Borrowing Costs
Tensions Rise Over Planned Pro-Palestinian March in London
Bomb Scare in Central London: Abandoned Car Sparks Panic Near Regent Street
Police Seek Suspect in Antisemitic Incident at Liverpool Street Station
Regulatory Reprimand for London Charity Over Fundraising for Israeli Soldier
The Duchess of Sussex Mourns Devastating Loss of Beloved Rescue Dog
From Chairman to Controversial Politician: Rupert Lowe's Journeys in Business and Politics
Metropolitan Police Halts Pro-Palestine March Near BBC Due to Proximity to Synagogue
Inside Warwick Hospital: A Glimpse into the NHS's Battle Against Winter Pressures
Chappell Roan: A Synth-Pop Sensation Emerges as BBC Sound Of 2025 Winner
Search Intensifies for Missing Aberdeen Sisters Eliza and Henrietta Huszti
Pioneering Drug Consumption Room Opens in Glasgow
×